Search results for "Highlights"


 
Results 51 - 60 of about 440 for "Highlights".
Sort by: Relevance | Newest | Oldest

HbA1c-based screening of general population reduced time to diabetes diagnosis

In a British database, 1% of participants ages 40 to 70 years had undiagnosed diabetes. Researchers estimated that population-based screening using HbA1c level could have reduced the time to diagnosis in this group by a median of 2.2 years.
https://diabetes.acponline.org/archives/2022/12/09/2.htm
9 Dec 2022

Updated guideline on managing hyperosmolar hyperglycemic state issued by U.K. experts

The recommendations from the Joint British Diabetes Societies for Inpatient Care Group cover clinical assessment and monitoring, interventions, and assessments and prevention of harm, as well as five phases of therapy.
https://diabetes.acponline.org/archives/2022/12/09/3.htm
9 Dec 2022

Self-monitoring of blood glucose reduced HbA1c in noninsulin-treated patients

Self-monitoring of blood glucose 8 to 11 times a week was more effective than doing so more or less frequently, according to a new meta-analysis.
https://diabetes.acponline.org/archives/2022/12/09/1.htm
9 Dec 2022

Diabetes and prior CVD may no longer carry equivalent cardiovascular risk

In a population-based Canadian study, the magnitude of the association between diabetes and risk of cardiovascular events decreased while that between cardiovascular disease (CVD) and such events remained stable.
https://diabetes.acponline.org/archives/2022/11/11/3.htm
11 Nov 2022

Annual screening for albuminuria may not be necessary in all patients with type 1 diabetes

A recent study found that personalizing the timing of testing based on patients' albumin excretion rate and HbA1c level could reduce time with undetected kidney disease as well as testing frequency.
https://diabetes.acponline.org/archives/2022/11/11/2.htm
11 Nov 2022

Newer oral diabetes meds could provide significant benefits in type 1 diabetes

A retrospective chart review found that glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors were associated with benefits including weight loss and reduced use of insulin in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2022/11/11/1.htm
11 Nov 2022

Spotlight on diabetes drug class comparisons

A large trial compared insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) receptor agonist, and a dipeptidyl peptidase-4 inhibitor as second-line therapy, while a modeling study considered GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as first-line agents.
https://diabetes.acponline.org/archives/2022/10/14/5.htm
14 Oct 2022

Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find

A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022

Time-restricted eating may help improve metabolic status

People who time-restricted their eating had decreased body weight and fat mass and improved lipid values but did not show improvements in waist circumference, HbA1c level, or blood pressure, a systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2022/10/14/2.htm
14 Oct 2022

Avoiding hypoglycemia most compelling reason for deintensifying diabetes meds

Researchers presented older adults with type 2 diabetes with three scenarios in which deintensification may be indicated—poor health, limited life expectancy, and high hypoglycemia risk—and found that 8%, 4%, and 75%, respectively, viewed deintensification positively.
https://diabetes.acponline.org/archives/2022/10/14/3.htm
14 Oct 2022

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next